In contrast, a benefit from PARP inhibitors in pancreatic cancer in other settings, such as somatic BRCA1/BRCA2 mutations, and in pancreatic cancers with mutations in non-BRCA1/BRCA2 DNA damage response (DDR)-associated genes is less clear. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.